Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 7, 2022; 28(29): 3981-3993
Published online Aug 7, 2022. doi: 10.3748/wjg.v28.i29.3981
Published online Aug 7, 2022. doi: 10.3748/wjg.v28.i29.3981
Table 4 Postoperative morbidity and recurrence status (n = 30)
| Resection, n = 15 | TACE, n = 15 | Total, n = 30 | P value | |
| Number of treatments | 1 ± 0 | 2.4 ± 1.1 | 1.7 ± 1.1 | 0.001 |
| Complications, n (%) | 0.876 | |||
| No | 8 (57.1) | 9 (60) | 17 (58.6) | |
| Yes | 6 (42.9) | 6 (40) | 12 (41.4) | |
| Missing | 1 | - | 1 | |
| Complications, n (%) | 0.545 | |||
| CD 1-2 | 5 (83.3) | 5 (83.3) | 10 | |
| CD 3-4 | 1 (16.7) | 1 (16.7) | 2 (16.7) | |
| Hospital stay (days) | 7 ± 3 | 5 ± 5 | 6 ± 4.3 | 0.224 |
| Recurrence, n (%) | 0.006 | |||
| No | 7 (46.7) | 0 | 7 (23.3) | |
| Yes | 8 (53.3) | 15 (100) | 23 (76.7) |
- Citation: Risaliti M, Bartolini I, Campani C, Arena U, Xodo C, Adotti V, Rosi M, Taddei A, Muiesan P, Amedei A, Batignani G, Marra F. Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis. World J Gastroenterol 2022; 28(29): 3981-3993
- URL: https://www.wjgnet.com/1007-9327/full/v28/i29/3981.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i29.3981